Evidence map›Paper›PMID 28677272›Full record

ArticlePharmaceutical statistics2017

Bayesian nonparametric statistics: A new toolkit for discovery in cancer research.

Peter F Thall, Peter Mueller, Yanxun Xu, Michele Guindani

Open access · greenAbstract read
In one paragraph

Article in Pharmaceutical statistics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Utility-based Bayesian personalized treatment selection for advanced breast cancer.Journal of the Royal Statistical Society. Series C, Applied statistics · 2022
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Peter F ThallDepartment of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7293-529X
Peter MuellerDepartment of Mathematics, University of Texas at Austin, Austin, TX, USA.
Yanxun XuDepartment of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, MD, USA.
Michele GuindaniDepartment of Statistics, University of California, Irvine, Irvine, CA, USA.
Johns Hopkins University · USThe University of Texas at Austin · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, Irvine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
STATISTICAL METHODS FOR COMPLEX CANCER TRIALSR01CA083932 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THALL, PETER F · 2000 to 2017
$2.3M
Statistical Methods and Software for More Efficient, Ethical, and Affordable ClinR01CA157458 · NCI · UNIVERSITY OF MINNESOTA · PI CARLIN, BRADLEY P · 2012 to 2014
$939k
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA083932NCI NIH HHS R01 CA157458
6 · The paper itself

Abstract

Many commonly used statistical methods for data analysis or clinical trial design rely on incorrect assumptions or assume an over-simplified framework that ignores important information. Such statistical practices may lead to incorrect conclusions about treatment effects or clinical trial designs that are impractical or that do not accurately reflect the investigator's goals. Bayesian nonparametric (BNP) models and methods are a very flexible new class of statistical tools that can overcome such limitations. This is because BNP models can accurately approximate any distribution or function and can accommodate a broad range of statistical problems, including density estimation, regression, survival analysis, graphical modeling, neural networks, classification, clustering, population models, forecasting and prediction, spatiotemporal models, and causal inference. This paper describes 3 illustrative applications of BNP methods, including a randomized clinical trial to compare treatments for intraoperative air leaks after pulmonary resection, estimating survival time with different multi-stage chemotherapy regimes for acute leukemia, and evaluating joint effects of targeted treatment and an intermediate biological outcome on progression-free survival time in prostate cancer.

Indexed as

Bayes TheoremResearch DesignAntineoplastic AgentsClinical Trials as TopicData Interpretation, StatisticalDisease-Free SurvivalHumansModels, StatisticalMolecular Targeted TherapyNeoplasmsRandomized Controlled Trials as TopicStatistics, NonparametricSurvival AnalysisAntineoplastic AgentsBayesian nonparametric statisticsclinical trial designdensity estimationdynamic treatment regimetargeted therapy

Identifiers

PMID28677272
PMCPMC5681362
OpenAlexW2730413727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.